Literature DB >> 25512404

In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model.

Alexander J Lepak1, Karen Marchillo2, William A Craig1, David R Andes3.   

Abstract

NAI-107 is a novel lantibiotic compound with potent in vitro activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The purpose of this study was to examine the activity of NAI-107 against S. aureus strains, including MRSA, in the neutropenic murine thigh infection model. Serum pharmacokinetics were determined and time-kill studies were performed following administration of single subcutaneous doses of 5, 20, and 80 mg/kg body weight. The dose fractionation included total doses ranging from 1.56 to 400 mg/kg/72 h, divided into 1, 2, 3, or 6 doses. Studies of treatment effects against 9 S. aureus strains (4 methicillin-susceptible Staphylococcus aureus [MSSA] and 5 MRSA) using a 12-h dosing interval and total dose range of 1.56 to 400 mg/kg/72 h were also performed. A maximum effect (Emax) model was used to determine the pharmacokinetic/pharmacodynamic (PK/PD) index that best described the dose-response data and to estimate the doses required to achieve a net bacteriostatic dose (SD) and a 1-log reduction in CFU/thigh. The pharmacokinetic studies demonstrated an area under the concentration-time curve (AUC) range of 26.8 to 276 mg·h/liter and half-lives of 4.2 to 8.2 h. MICs ranged from 0.125 to 0.5 μg/ml. The 2 highest single doses produced more than a 2-log kill and prolonged postantibiotic effects (PAEs) ranging from 36 to >72 h. The dose fractionation-response curves were similar, and the AUC/MIC ratio was the most predictive PD index (AUC/MIC, coefficient of determination [R2]=0.89; maximum concentration of drug in serum [Cmax]/MIC, R2=0.79; time [T]>MIC, R2=0.63). A ≥2-log kill was observed against all 9 S. aureus strains. The total drug 24-h AUC/MIC values associated with stasis and a 1-log kill for the 9 S. aureus strains were 371±130 and 510±227, respectively. NAI-107 demonstrated concentration-dependent killing and prolonged PAEs. The AUC/MIC ratio was the predictive PD index. Extensive killing was observed for S. aureus organisms, independent of the MRSA status. The AUC/MIC target should be useful for the design of clinical dosing regimens.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25512404      PMCID: PMC4335879          DOI: 10.1128/AAC.04444-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  45 in total

1.  The perpetual challenge of infectious diseases.

Authors:  Anthony S Fauci; David M Morens
Journal:  N Engl J Med       Date:  2012-02-02       Impact factor: 91.245

Review 2.  Mechanisms of resistance and clinical relevance of resistance to β-lactams, glycopeptides, and fluoroquinolones.

Authors:  Louis B Rice
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

Review 3.  New horizons for host defense peptides and lantibiotics.

Authors:  Michael John Dawson; Richard W Scott
Journal:  Curr Opin Pharmacol       Date:  2012-07-07       Impact factor: 5.547

4.  Combating antimicrobial resistance: policy recommendations to save lives.

Authors:  Brad Spellberg; Martin Blaser; Robert J Guidos; Helen W Boucher; John S Bradley; Barry I Eisenstein; Dale Gerding; Ruth Lynfield; L Barth Reller; John Rex; David Schwartz; Edward Septimus; Fred C Tenover; David N Gilbert
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

5.  The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020.

Authors: 
Journal:  Clin Infect Dis       Date:  2010-04-15       Impact factor: 9.079

Review 6.  Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci, and other Gram-positives in healthcare.

Authors:  David P Calfee
Journal:  Curr Opin Infect Dis       Date:  2012-08       Impact factor: 4.915

7.  Efficacy of the new lantibiotic NAI-107 in experimental infections induced by multidrug-resistant Gram-positive pathogens.

Authors:  Daniela Jabés; Cristina Brunati; GianPaolo Candiani; Simona Riva; Gabriella Romanó; Stefano Donadio
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

8.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.

Authors:  Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2011-02-01       Impact factor: 9.079

9.  Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007.

Authors:  Deron C Burton; Jonathan R Edwards; Teresa C Horan; John A Jernigan; Scott K Fridkin
Journal:  JAMA       Date:  2009-02-18       Impact factor: 56.272

10.  The lantibiotic NAI-107 binds to bactoprenol-bound cell wall precursors and impairs membrane functions.

Authors:  Daniela Münch; Anna Müller; Tanja Schneider; Bastian Kohl; Michaela Wenzel; Julia Elisabeth Bandow; Sonia Maffioli; Margherita Sosio; Stefano Donadio; Reinhard Wimmer; Hans-Georg Sahl
Journal:  J Biol Chem       Date:  2014-03-13       Impact factor: 5.157

View more
  13 in total

Review 1.  Mechanistic Understanding of Lanthipeptide Biosynthetic Enzymes.

Authors:  Lindsay M Repka; Jonathan R Chekan; Satish K Nair; Wilfred A van der Donk
Journal:  Chem Rev       Date:  2017-01-30       Impact factor: 60.622

Review 2.  Advancing cell wall inhibitors towards clinical applications.

Authors:  Sonia I Maffioli; João C S Cruz; Paolo Monciardini; Margherita Sosio; Stefano Donadio
Journal:  J Ind Microbiol Biotechnol       Date:  2015-10-29       Impact factor: 3.346

3.  Characterization of the stereochemical configuration of lanthionines formed by the lanthipeptide synthetase GeoM.

Authors:  Neha Garg; Yuki Goto; Ting Chen; Wilfred A van der Donk
Journal:  Biopolymers       Date:  2016-11       Impact factor: 2.505

4.  Antibacterial activity of the novel semisynthetic lantibiotic NVB333 in vitro and in experimental infection models.

Authors:  Steven Boakes; William J Weiss; Mary Vinson; Sjoerd Wadman; Michael J Dawson
Journal:  J Antibiot (Tokyo)       Date:  2016-05-18       Impact factor: 2.649

5.  Pharmacokinetics and pharmacodynamics of enrofloxacin treatment of Escherichia coli in a murine thigh infection modeling.

Authors:  Xuesong Liu; Qingwen Yang; Yuying Fan; Yuanyi Du; Lei Lei; Dong Wang; Yun Liu
Journal:  BMC Vet Res       Date:  2021-06-09       Impact factor: 2.741

6.  The Lantibiotic NAI-107 Efficiently Rescues Drosophila melanogaster from Infection with Methicillin-Resistant Staphylococcus aureus USA300.

Authors:  Thomas T Thomsen; Biljana Mojsoska; João C S Cruz; Stefano Donadio; Håvard Jenssen; Anders Løbner-Olesen; Kim Rewitz
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

7.  Elucidating the molecular physiology of lantibiotic NAI-107 production in Microbispora ATCC-PTA-5024.

Authors:  Giuseppe Gallo; Giovanni Renzone; Emilia Palazzotto; Paolo Monciardini; Simona Arena; Teresa Faddetta; Anna Giardina; Rosa Alduina; Tilmann Weber; Fabio Sangiorgi; Alessandro Russo; Giovanni Spinelli; Margherita Sosio; Andrea Scaloni; Anna Maria Puglia
Journal:  BMC Genomics       Date:  2016-01-12       Impact factor: 3.969

8.  Expanding the potential of NAI-107 for treating serious ESKAPE pathogens: synergistic combinations against Gram-negatives and bactericidal activity against non-dividing cells.

Authors:  Cristina Brunati; Thomas T Thomsen; Eleonora Gaspari; Sonia Maffioli; Margherita Sosio; Daniela Jabes; Anders Løbner-Olesen; Stefano Donadio
Journal:  J Antimicrob Chemother       Date:  2018-02-01       Impact factor: 5.790

9.  A Novel Microbisporicin Producer Identified by Early Dereplication during Lantibiotic Screening.

Authors:  Lucia Carrano; Monica Abbondi; Paola Turconi; Gianpaolo Candiani; Flavia Marinelli
Journal:  Biomed Res Int       Date:  2015-08-04       Impact factor: 3.411

10.  Cytological Profile of Antibacterial FtsZ Inhibitors and Synthetic Peptide MciZ.

Authors:  Lidia Araújo-Bazán; Laura B Ruiz-Avila; David Andreu; Sonia Huecas; José M Andreu
Journal:  Front Microbiol       Date:  2016-10-03       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.